EGF and myelodysplastic syndrome: Only four mediators varied differently for high- and low-risk MDS patients; CXCL11 was significantly decreased only for low-risk patients compared to controls (p = 0.014) whereas CD40L (p = 0.003) and EGF (p = 0.008) were decreased only for the high-risk patients.